About
Contact
Help
Sending publications
How to publish
Advanced Search
View Item 
  •   Home
  • Facultad de Medicina
  • Artículos de revistas
  • View Item
  •   Home
  • Facultad de Medicina
  • Artículos de revistas
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browse byCommunities and CollectionsDateAuthorsTitlesSubjectsThis CollectionDateAuthorsTitlesSubjects

My Account

Login to my accountRegister
Biblioteca Digital - Universidad de Chile
Revistas Chilenas
Repositorios Latinoamericanos
Tesis LatinoAmericanas
Tesis chilenas
Related linksRegistry of Open Access RepositoriesOpenDOARGoogle scholarCOREBASE
My Account
Login to my accountRegister

Hemofilia adquirida tratada con anti-CD20, un anticuerpo anti linfocito B

Artículo
Thumbnail
Open/Download
IconConte_Guillermo.pdf (244.9Kb)
Publication date
2011-03
Metadata
Show full item record
Cómo citar
Conte Lanza, Guillermo
Cómo citar
Hemofilia adquirida tratada con anti-CD20, un anticuerpo anti linfocito B
.
Copiar
Cerrar

Author
  • Conte Lanza, Guillermo;
  • Figueroa Maureira, Gastón;
  • Aravena Rodríguez, Paola Carolina;
  • González Gómez, Néstor;
  • Araos H., Daniel;
  • Cuneo V., Mariana;
Abstract
We report a 54-year-old male presenting with a history or recurrent nose bleeds and ecchymoses. The coagulation study showed a prolonged partial thromboplastin time, a factor VIII of 8% and a high inhibitor titer (193 Bethesda units). A diagnosis of acquired hemophilia A was reached. The patient was initially treated with cyclophosphamide for seven months without response. Therefore rituximab in doses of 375 mg/m2/week for four weeks was started. After starting treatment, the patient had a hematoma in the psoas muscle with a concomitant factor VIII of less than 5%, that was treated with local measures. Thereafter, a progressive reduction in inhibitor titers was observed, until its disappearance at fi ve months of treatment. Factor VIII levels normalized and the patient has not experienced abnormal bleeding episodes. The patient remains in remission after 67 months of follow up. Rituximab, a chimeric monoclonal antibody against the protein CD 20 is an effective treatment in acquired hemophilia A.
General note
Artículo de publicación ISI
Identifier
URI: https://repositorio.uchile.cl/handle/2250/128880
ISSN: 0034-9887
Quote Item
REVISTA MEDICA DE CHILE Volume: 139 Issue: 3 Pages: 357-361 Published: MAR 2011
Collections
  • Artículos de revistas
xmlui.footer.title
31 participating institutions
More than 73,000 publications
More than 110,000 topics
More than 75,000 authors
Published in the repository
  • How to publish
  • Definitions
  • Copyright
  • Frequent questions
Documents
  • Dating Guide
  • Thesis authorization
  • Document authorization
  • How to prepare a thesis (PDF)
Services
  • Digital library
  • Chilean academic journals portal
  • Latin American Repository Network
  • Latin American theses
  • Chilean theses
Dirección de Servicios de Información y Bibliotecas (SISIB)
Universidad de Chile

© 2020 DSpace
  • Access my account